To improve commercialization activities in the SBIR and STTR programs, and for other purposes.
Summary
What This Bill Does
The bill expands SBIR/STTR phase flexibility authority from only NIH, DOD, and Education (through 2025) to all federal agencies with SBIR/STTR programs (FY2025-2027), requires each federal agency with SBIR/STTR program to designate a Technology Commercialization Official with commercialization experience to guide awardees, identify Phase III transition opportunities, coordinate, and creates overhauls SBIR/STTR technical assistance: changes from permissive vendor-selected assistance to mandatory recipient-directed assistance. It relies on reporting requirements, grants, exemptions, and compliance mandates. The main policy areas are Finance, Trade, Technology, and Healthcare.
Who Benefits and How
Small businesses with SBIR/STTR awards could gain revenue opportunities, Small businesses with SBIR/STTR awards seeking patents could face fewer barriers, and Small businesses seeking to commercialize SBIR/STTR research could face fewer barriers.
Who Bears the Burden and How
Small Business Administration would take on compliance duties, Federal agencies with SBIR/STTR programs would take on compliance duties, and United States Patent and Trademark Office would take on compliance duties.
Key Provisions
- Expands SBIR/STTR phase flexibility authority from only NIH, DOD, and Education (through 2025) to all federal agencies with SBIR/STTR programs (FY2025-2027).
- Requires each federal agency with SBIR/STTR program to designate a Technology Commercialization Official with commercialization experience to guide awardees, identify Phase III transition opportunities, coordinate...
- Creates overhauls SBIR/STTR technical assistance: changes from permissive vendor-selected assistance to mandatory recipient-directed assistance.
- Requires federal agencies with I-Corps programs to provide SBIR/STTR awardees the option to participate in I-Corps teams courses and use technical assistance funding for participation.
- Creates an annual commercialization impact assessment for small businesses with 50+ Phase II awards over 9 years, tracking: federal award values, SBIR/STTR award values, gross revenue, product/licensing revenue...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill expands SBIR/STTR phase flexibility authority from only NIH, DOD, and Education (through 2025) to all federal agencies with SBIR/STTR programs (FY2025-2027), requires each federal agency with SBIR/STTR program to designate a Technology Commercialization Official with commercialization experience to guide awardees, identify Phase III transition opportunities, coordinate, and creates overhauls SBIR/STTR technical assistance: changes from permissive vendor-selected assistance to mandatory recipient-directed assistance.
Key Policy Areas
Finance, Trade, Technology, Healthcare
Primary Purpose
The bill expands SBIR/STTR phase flexibility authority from only NIH, DOD, and Education (through 2025) to all federal agencies with SBIR/STTR programs (FY2025-2027), requires each federal agency with SBIR/STTR program to designate a Technology Commercialization Official with commercialization experience to guide awardees, identify Phase III transition opportunities, coordinate, and creates overhauls SBIR/STTR technical assistance: changes from permissive vendor-selected assistance to mandatory recipient-directed assistance.
Policy Domains
Section 2 - Commercialization selection improvements (peer review)
Identified Gains
- Small businesses with SBIR/STTR awards
- Small businesses with SBIR/STTR awards seeking patents
- Small businesses seeking to commercialize SBIR/STTR research
- Technology commercialization consultants and service providers
- I-Corps program (NSF and participating agencies)
Identified Costs
- Small Business Administration
- Federal agencies with SBIR/STTR programs
- United States Patent and Trademark Office
Sponsors
Legislative Progress
IntroducedMr. Coons (for himself and Mr. Curtis) introduced the following …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Small businesses seeking to commercialize SBIR/STTR research, Small businesses with SBIR/STTR awards, Small businesses with SBIR/STTR awards seeking patents
Federal agencies with SBIR/STTR programs, I-Corps program (NSF and participating agencies), Small Business Administration
Positive-direction: I-Corps program (NSF and participating agencies)
Negative-direction: Federal agencies with SBIR/STTR programs, Small Business Administration, United States Patent and Trademark Office
Technology commercialization consultants and service providers
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "nih"
- → National Institutes of Health
- "sba"
- → Small Business Administration
- "sba"
- → SBA Administrator
- "sba"
- → SBA Administrator
- "uspto"
- → Director of USPTO
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology